- Home
- RIGL vs EBF Comparison
RIGL vs EBF Comparison
Compare RIGL & EBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | EBF |
|---|---|---|
| Founded | 1996 | 1909 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 533.9M |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RIGL | EBF |
|---|---|---|
| Price | $29.20 | $20.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 386.9K | 138.1K |
| Earning Date | 05-05-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 4.85% |
| EPS Growth | ★ 1867.68 | 7.79 |
| EPS | 0.44 | ★ 1.66 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | $66.97 | ★ $12.07 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.14 | $16.30 |
| 52 Week High | $52.24 | $22.36 |
Technical Indicators
Market Signals| Indicator | RIGL | EBF |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 45.10 |
| Support Level | $28.08 | $20.10 |
| Resistance Level | $32.17 | $21.39 |
| Average True Range (ATR) | 1.99 | 0.40 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 48.15 | 40.27 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About EBF Ennis Inc.
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.